Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AM-21 + QTsome
- Development stage
- Preclinical
- Lead developer
- Haichang Biotech
- Modality
- Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous
01
Overview
AM-21 + QTsome (also known as WGI-2101 or MyMiR) is an experimental, preclinical antisense oligonucleotide therapeutic delivered via a lipid nanoparticle (LNP) platform. The active ingredient, AM-21 (antimiR-21), is a synthetic oligonucleotide designed to target and inhibit microRNA-21 (miR-21), an oncogenic microRNA (oncomiR) frequently upregulated in various human cancers, including non-small cell lung cancer (NSCLC) and colorectal cancer. QTsome is a pH-responsive LNP delivery vehicle combining quaternary amine cationic lipids and tertiary amine ionizable lipids to optimize drug loading and endosomal release. In preclinical models, AM-21 + QTsome has demonstrated significant tumor growth inhibition, upregulation of downstream miR-21 targets such as PTEN and DDAH1, and synergistic effects when combined with chemotherapeutic agents like paclitaxel or targeted therapies like erlotinib. An optimized formulation, QTPlus-AM21, has also been evaluated in combination with the immune checkpoint inhibitor atezolizumab.
- Brand names
- MyMiR
- Other names
- AM-21/QTsomeQTPlus-AM21QTPlus-AM-21QTPlus-AM 21QTsome/AM-21anti-miR-21 + QTsomeantimiR-21 + QTsome
02
Targets
miR-21 (MicroRNA-21)
Beyond the preview
Go deeper on AM-21 + QTsome.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AM-21 + QTsome.